ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Based on these results, further validation is essential, including clinical practice verification of cross‐resistance, comparing asciminib resistance in samples taken at the time of initial CML onset with that in samples taken at the time of resistance to BCR‐ABL inhibitors.